Humanigen Inc (HGENQ)

[cowtown jay]

"Based on the patient inclusion criteria, the LIVE-AIR patients were conservatively in ordinal scales 4 or 5 of the WHO's disease severity scale."

Unfortunately, I can't be conservative by reducing the ordinal scale range of patients in the LIVE-AIR trial.

I have to say that LIVE-AIR patients were in ordinal scales 3, 4, and 5.

And that ACTIV-5 patients were in ordinal scales 5, 6, and 7.

This is due to two facts. One fact being the NIH Covid-19 Treatment Guidelines, which recognized that, "Data from a double-blind randomized controlled trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor..." and that, "...the lenzilumab and mavrilimumab studies primarily included patients on room air or low-flow oxygen and excluded patients receiving mechanical ventilation."

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/gm-csf-inhibitors/

And secondly, the company had reported that ~60% of the LIVE-AIR patients were on room air +. Plus what, I don't recall the degree of supplemental oxygen.

I made a big deal about this previously, as I think I should have.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169869278